Author pages are created from data sourced from our academic publisher partnerships and public sources.
Synthesis of antihemophilic factor antigen by cultured human endothelial cells.
Antihemophilic factor (AHF, Factor VIII) antigen has been demonstrated in cultured human endothelial cells by immunofluorescence studies using monospecific rabbit antibody to human AHF. Control… Expand
Synthesis of von Willebrand factor by cultured human endothelial cells.
- E. Jaffe, L. Hoyer, R. Nachman
- Biology, Medicine
- Proceedings of the National Academy of Sciences…
- 1 May 1974
Cultured human endothelial cells synthesize and secrete a protein(s) which has Factor VIII antigen but which lacks Factor VIII clot-promoting activity (J. Clin. Invest. 52, 2757-2764, 1973). Von… Expand
Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
The finding that human factor VIII (fVIII) inhibitor antibodies with C2 domain epitopes interfere with the binding of fVIII to phosphatidylserine (PS) suggested that this is the mechanism by which… Expand
Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.
The size of human factor VIII-related protein in plasma has been determined by sodium dodecyl sulfate (SDS) glyoxyl agarose electrophoresis. The protein was immobilized after the electrophoresis by… Expand
The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors.
- C. McMillan, S. Shapiro, D. Whitehurst, L. Hoyer, A. V. Rao, J. Lazerson
- 1 February 1988
During a 4-year multicenter cooperative study of acquired factor VIII inhibitors in persons with hemophilia A, new inhibitors were detected in 31 of 1,306 patients who entered the study without an… Expand
Transgenic pigs produce functional human factor VIII in milk
Deficiency or abnormality of coagulation factor VIII (FVIII) causes a bleeding disorder called hemophilia A. Treatment involves FVIII concentrates prepared from pooled human plasma or recombinant… Expand
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
- H. Weiss, L. Hoyer, F. Rickles, A. Varma, J. Rogers
- Chemistry, Medicine
- The Journal of clinical investigation
- 1 November 1973
In a previous paper, we showed that the abnormality of ristocetin-induced platelet aggregation in platelet-rich plasma in 10 patients with von Willebrand's disease could be corrected by a factor in… Expand
Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
In normal plasma, the ratio of the procoagulant activity of factor VIII (VIII(AHF)) to that of the von Willebrand factor activity (ristocetin cofactor, VIII(VWF)) or factor VIII antigen (VIII(AGN))… Expand
Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin.
Desmopressin was administered intravenously to 68 patients with hemophilia and von Willebrand's disease of mild or moderate severity to assess the safety, reproducibility, and range of response to… Expand